DOCSLIB.ORG

Advances in Aggressive Lymphoma from the 2017 American Society Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

February 2018 Volume 16, Issue 2, Supplement 5 A SPECIAL MEETING REVIEW EDITION Advances in Aggressive Lymphoma From the 2017 American Society of Hematology Annual Meeting and Exposition A Review of Selected Presentations From the 2017 American Society of Hematology Annual Meeting and Exposition • December 9-12, 2017 • Atlanta, Georgia Special Reporting on: • Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma • Primary Analysis of JULIET: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma • A Comparison of One Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients With Refractory, Aggressive Non-Hodgkin Lymphoma • High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated With the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort • Phase 1 Results From ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination With Atezolizumab for the Treatment of Patients With Refractory Diffuse Large B-Cell Lymphoma • Effect of Rituximab in Primary Central Nervous System Lymphoma—Results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study • Encouraging Early Results From the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/ Refractory B-Cell Lineage Non-Hodgkin Lymphoma PLUS Meeting Abstract Summaries With Expert Commentary by: Frederick L. Locke, MD Vice Chair and Associate Member Department of Blood and Marrow Transplant and Cellular Immunotherapy Moffitt Cancer Center Tampa, Florida ON THE WEB: hematologyandoncology.net Indexed through the National Library of Medicine (PubMed/MEDLINE), PubMed Central (PMC), and EMBASE IMPORTANT SAFETY INFORMATION (continued) SERIOUS INFECTIONS Severe or life-threatening infections occurred in patients after YESCARTA™ infusion. CYTOKINE RELEASE SYNDROME (CRS) In Study 1, infections (all grades) occurred in 38% of patients. Grade 3 or higher CRS, including fatal or life-threatening reactions, occurred following treatment infections occurred in 23% of patients. Grade 3 or higher infections with an unspecified with YESCARTA™. In Study 1, CRS occurred in 94% (101/108) of patients receiving pathogen occurred in 16% of patients, bacterial infections in 9%, and viral infections YESCARTA™, including ≥ Grade 3 (Lee grading system) CRS in 13% (14/108) of in 4%. YESCARTA™ should not be administered to patients with clinically significant patients. Among patients who died after receiving YESCARTA™, four had ongoing active systemic infections. Monitor patients for signs and symptoms of infection before CRS events at the time of death. The median time to onset was 2 days (range: and after YESCARTA™ infusion and treat appropriately. Administer prophylactic anti- 1 to 12 days) and the median duration of CRS was 7 days (range: 2 to 58 days). microbials according to local guidelines. Key manifestations of CRS include fever (78%), hypotension (41%), tachycardia Febrile neutropenia was observed in 36% of patients after YESCARTA™ infusion (28%), hypoxia (22%), and chills (20%). Serious events that may be associated and may be concurrent with CRS. In the event of febrile neutropenia, evaluate with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular for infection and manage with broad spectrum antibiotics, fluids and other tachycardia), cardiac arrest, cardiac failure, renal insufficiency, capillary leak supportive care as medically indicated. syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/ macrophage activation syndrome (HLH/MAS) [see Adverse Reactions (6)]. Viral Reactivation Ensure that 2 doses of tocilizumab are available prior to infusion of YESCARTA™. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, Monitor patients at least daily for 7 days at the certified healthcare facility hepatic failure and death, can occur in patients treated with drugs directed against B following infusion for signs and symptoms of CRS. Monitor patients for signs or cells. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines symptoms of CRS for 4 weeks after infusion. Counsel patients to seek immediate before collection of cells for manufacturing. medical attention should signs or symptoms of CRS occur at any time [see PROLONGED CYTOPENIAS Patient Counseling Information (17)]. At the first sign of CRS, institute treatment Patients may exhibit cytopenias for several weeks following lymphodepleting with supportive care, tocilizumab or tocilizumab and corticosteroids as indicated chemotherapy and YESCARTA™ infusion. In Study 1, Grade 3 or higher [see Dosage and Administration (2.3)]. cytopenias not resolved by Day 30 following YESCARTA™ infusion occurred in NEUROLOGIC TOXICITIES 28% of patients and included thrombocytopenia (18%), neutropenia (15%), and INTRODUCING A NEW Neurologic toxicities, that were fatal or life-threatening, occurred following anemia (3%). Monitor blood counts after YESCARTA™ infusion. treatment with YESCARTA™. Neurologic toxicities occurred in 87% of patients. HYPOGAMMAGLOBULINEMIA Ninety-eight percent of all neurologic toxicities occurred within the first 8 weeks B-cell aplasia and hypogammaglobulinemia can occur in patients receiving of YESCARTA™ infusion, with a median time to onset of 4 days (range: 1 to 43 treatment with YESCARTA™. In Study 1, hypogammaglobulinemia occurred in 15% days). The median duration of neurologic toxicities was 17 days. Grade 3 or higher of patients. Monitor immunoglobulin levels after treatment with YESCARTA™ and neurologic toxicities occurred in 31% of patients. manage using infection precautions, antibiotic prophylaxis and immunoglobulin CAR T THERAPY The most common neurologic toxicities included encephalopathy (57%), replacement. headache (44%), tremor (31%), dizziness (21%), aphasia (18%), delirium (17%), The safety of immunization with live viral vaccines during or following insomnia (9%) and anxiety (9%). Prolonged encephalopathy lasting up to 173 days YESCARTA™ treatment has not been studied. Vaccination with live virus vaccines was noted. Serious events including leukoencephalopathy and seizures occurred is not recommended for at least 6 weeks prior to the start of lymphodepleting Find a list of authorized treatment centers with YESCARTA™. Fatal and serious cases of cerebral edema have occurred in chemotherapy, during YESCARTA™ treatment, and until immune recovery patients treated with YESCARTA™. following treatment with YESCARTA™. at YESCARTA.com/centers Monitor patients at least daily for 7 days at the certified healthcare facility following infusion for signs and symptoms of neurologic toxicities. Monitor SECONDARY MALIGNANCIES patients for signs or symptoms of neurologic toxicities for 4 weeks after infusion Patients treated with YESCARTA™ may develop secondary malignancies. Monitor and treat promptly [see Management of Severe Adverse Reactions (2.3); Neurologic life-long for secondary malignancies. In the event that a secondary malignancy Toxicities]. occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient INDICATION samples to collect for testing. YESCARTA™ REMS YESCARTA™ is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult Because of the risk of CRS and neurologic toxicities, YESCARTA™ is available EFFECTS ON ABILITY TO DRIVE AND USE MACHINES patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large only through a restricted program under a Risk Evaluation and Mitigation Due to the potential for neurologic events, including altered mental status or B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, Strategy (REMS) called the YESCARTA™ REMS [see Boxed Warning and Warnings seizures, patients receiving YESCARTA™ are at risk for altered or decreased and DLBCL arising from follicular lymphoma. and Precautions (5.1 and 5.2)]. The required components of the YESCARTA™ REMS consciousness or coordination in the 8 weeks following YESCARTA™ infusion. Limitation of Use: YESCARTA™ is not indicated for the treatment of patients with primary central nervous system lymphoma. are: Advise patients to refrain from driving and engaging in hazardous occupations • Healthcare facilities that dispense and administer YESCARTA™ must be or activities, such as operating heavy or potentially dangerous machinery, during IMPORTANT SAFETY INFORMATION enrolled and comply with the REMS requirements. Certified healthcare this initial period. facilities must have on-site, immediate access to tocilizumab, and ensure ADVERSE REACTIONS WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITIES that a minimum of two doses of tocilizumab are available for each patient for The most common adverse reactions (incidence ≥ 20%) include CRS, fever, • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving infusion within 2 hours after YESCARTA™ infusion, if needed for treatment of hypotension, encephalopathy, tachycardia, fatigue, headache, decreased appetite, YESCARTA™. Do not administer YESCARTA™ to patients with active infection or inflammatory
Recommended publications
  • Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor

    Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor

    Jefferies Global Healthcare Conference June 2, 2015 Forward Looking Statements / Safe Harbor To the extentstatements contained in this presentation are not descriptionsof historical facts regarding Kite Pharma, Inc. (“Kite,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward- looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: (i) the success, cost and timing of our product development activities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) to continue research and development activities relating to our product candidates; (iii) our ability to obtain and maintain regulatory approval of KTE-C19 and any other product candidates; (iv) our ability to obtain funding for our operations and further development and commercialization of our product candidates; (v) our plans to research and discover
  • Key Metrics for Recent Technology and Life Sciences Initial Public Offerings

    Key Metrics for Recent Technology and Life Sciences Initial Public Offerings

    H1 2014 Key Metrics for Recent Technology and Life Sciences Initial Public Offerings H1 2014 Key Metrics for Recent Technology and Life Sciences Initial Public Offerings H1 2014 Survey Introduction and Background This report has been developed as a resource for our clients and friends interested in understanding recent IPO activity of technology and life sciences companies. This information comprises a number of graphs and charts reflecting selected statistics that we believe provide useful information about activity in these markets. This is followed by the listing of technology and life sciences IPOs priced in the first half of 2014 and second half of 2013. We hope that you find this useful. Please contact Daniel J. Winnike at [email protected] or Jeffrey R. Vetter at [email protected] if you care to discuss this information or, as always, contact members of your client service team for more information. Survey Contents Survey Results ..................................................................................................................................................... 2 Offerings Completed ............................................................................................................................................. 3 Size of Offerings, Red Herring Midpoint ................................................................................................................. 4 Size of Offerings, Final IPO Price ...........................................................................................................................
  • Antibody Drug Conjugates in Lymphoma

    Antibody Drug Conjugates in Lymphoma

    Review: Clinical Trial Outcomes Nathwani & Chen Antibody drug conjugates in lymphoma 6 Review: Clinical Trial Outcomes Antibody drug conjugates in lymphoma Clin. Investig. (Lond.) Antibody drug conjugates (ADCs) are comprised of monoclonal antibodies physically Nitya Nathwani1 & Robert linked to cytotoxic molecules. They expressly target cancer cells by delivering cytotoxic Chen*,1 agents to cells displaying specific antigens, and minimize damage to normal tissue. The 1Department of Hematology & Hematopoietic Cell Transplantation, City efficacy and tolerability of these agents are primarily determined by the target antigen, of Hope, Duarte, CA, USA the cytotoxic agent and the linker connecting the cytotoxic agent to the monoclonal *Author for correspondence: antibody. Following advances in technology, clinical trials have demonstrated greater Tel.: +626 256 4673 (ext. 65298) efficacy for ADCs compared with the corresponding naked monoclonal antibodies. Fax: +626 301 8116 This review summarizes the features of current clinically active ADCs in lymphoma and [email protected] emphasizes recent clinical data elucidating the benefit of antibody-directed delivery of cytotoxic agents to tumor cells. Keywords: antibody drug conjugates • lymphoma • monoclonal antibodies Lymphoma is the most common hematologic concentration and poor performance status malignancy, and is subdivided into two main are adverse prognostic factors. SEER (Sur- types: Hodgkin lymphoma (HL) and non- veillance, Epidemiology and End Results) Hodgkin lymphoma (NHL). In the United data from the National Cancer Institute, States, there are an estimated 731,277 people 2013 has revealed a significant improvement 10.4155/CLI.14.73 living with or in remission from lymphoma. in survival rates in this group of diseases in In 2013, there were an estimated 79,030 new the last four decades.
  • CD20-Negative Diffuse Large B-Cell Lymphomas: Biology and Emerging Therapeutic Options

    CD20-Negative Diffuse Large B-Cell Lymphomas: Biology and Emerging Therapeutic Options

    Expert Review of Hematology ISSN: 1747-4086 (Print) 1747-4094 (Online) Journal homepage: http://www.tandfonline.com/loi/ierr20 CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options Jorge J Castillo, Julio C Chavez, Francisco J Hernandez-Ilizaliturri & Santiago Montes-Moreno To cite this article: Jorge J Castillo, Julio C Chavez, Francisco J Hernandez-Ilizaliturri & Santiago Montes-Moreno (2015) CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options, Expert Review of Hematology, 8:3, 343-354, DOI: 10.1586/17474086.2015.1007862 To link to this article: http://dx.doi.org/10.1586/17474086.2015.1007862 Published online: 01 Feb 2015. Submit your article to this journal Article views: 165 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierr20 Download by: [North Shore Med Ctr], [Jorge Castillo] Date: 16 March 2016, At: 07:44 Review CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options Expert Rev. Hematol. 8(3), 343–354 (2015) Jorge J Castillo*1, CD20-negative diffuse large B-cell lymphoma (DLBCL) is a rare and heterogeneous group of Julio C Chavez2, lymphoproliferative disorders. Known variants of CD20-negative DLBCL include plasmablastic Francisco J lymphoma, primary effusion lymphoma, large B-cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease and anaplastic lymphoma kinase-positive DLBCL. Hernandez-Ilizaliturri3 Given the lack of CD20 expression, atypical cellular morphology and aggressive clinical and Santiago 4 behavior characterized by chemotherapy resistance and inferior survival rates, CD20-negative Montes-Moreno DLBCL represents a challenge from the diagnostic and therapeutic perspectives.
  • Investment Thesis for Kite Pharma, Inc. (Nasdaq: Kite)

    Investment Thesis for Kite Pharma, Inc. (Nasdaq: Kite)

    SAF/No.14/March 2017 Studies in Applied Finance INVESTMENT THESIS FOR KITE PHARMA, INC. (NASDAQ: KITE) Samantha Semenkow Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise Investment Thesis for Kite Pharma, Inc. (Nasdaq: KITE) by Samantha Semenkow Investment Thesis for Kite Pharma, Inc. (Nasdaq: KITE) By Samantha Semenkow Disclaimer: These research reports are primarily student reports for academic purposes and are not specific recommendations to buy or sell a stock. Potential investors should consult a qualified investment advisor before making an investment. About the Series The Studies in Applied Finance series is under the direction of Professor Steve H. Hanke ([email protected]), Co-director of The Johns Hopkins Institute for Applied Economics, Global Health, and the Study for Business Enterprise, and Dr. Hesam Motlagh ([email protected]), a Fellow at the Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise. This working paper is one in a series on Applied Financial Economics that focuses on company valuations. The authors are mainly students at The Johns Hopkins University and The Johns Hopkins School of Medicine in Baltimore, MD who have conducted their work at the institute as undergraduate and graduate researchers. About the Author Samantha Semenkow ([email protected]) is a PhD candidate in the Pathobiology Graduate Program at The Johns Hopkins School of Medicine in Baltimore, MD. She conducted the research for this paper while serving as Professor Hanke’s research assistant at The Johns Hopkins Institute for Applied Economics, Global Health, and the Study of Business Enterprise during the Fall of 2016.
  • Gilead Sciences to Acquire Kite Pharma for $11.9 Billion

    Gilead Sciences to Acquire Kite Pharma for $11.9 Billion

    August 28, 2017 Gilead Sciences to Acquire Kite Pharma for $11.9 Billion -- Immediately Positions Gilead as a Leader in Cell Therapy -- -- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU -- -- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation -- -- Leverages Gilead's Expertise in Rapidly Advancing Therapies to Address Unmet Patient Needs -- FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170828005415/en/ Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S.
  • Drug Resistance in Non-Hodgkin Lymphomas

    Drug Resistance in Non-Hodgkin Lymphomas

    International Journal of Molecular Sciences Review Drug Resistance in Non-Hodgkin Lymphomas Pavel Klener 1,2,* and Magdalena Klanova 1,2 1 First Department of Internale Medicine-Hematology, University General Hospital in Prague, 128 08 Prague, Czech Republic; [email protected] 2 Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, 128 53 Prague, Czech Republic * Correspondence: [email protected] or [email protected] Received: 3 February 2020; Accepted: 15 March 2020; Published: 18 March 2020 Abstract: Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of malignant transformation of mature lymphocytes during various stages of differentiation. The WHO classification of NHL recognizes more than 90 nosological units with peculiar pathophysiology and prognosis. Since the end of the 20th century, our increasing knowledge of the molecular biology of lymphoma subtypes led to the identification of novel druggable targets and subsequent testing and clinical approval of novel anti-lymphoma agents, which translated into significant improvement of patients’ outcome. Despite immense progress, our effort to control or even eradicate malignant lymphoma clones has been frequently hampered by the development of drug resistance with ensuing unmet medical need to cope with relapsed or treatment-refractory disease. A better understanding of the molecular mechanisms that underlie inherent or acquired drug resistance might lead to the design of more effective front-line treatment algorithms based on reliable predictive markers or personalized salvage therapy, tailored to overcome resistant clones, by targeting weak spots of lymphoma cells resistant to previous line(s) of therapy. This review focuses on the history and recent advances in our understanding of molecular mechanisms of resistance to genotoxic and targeted agents used in clinical practice for the therapy of NHL.
  • Non-Hodgkin Lymphoma

    Non-Hodgkin Lymphoma

    Non-Hodgkin Lymphoma Rick, non-Hodgkin lymphoma survivor This publication was supported in part by grants from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) believes we are living at an extraordinary moment. LLS is committed to bringing you the most up-to-date blood cancer information. We know how important it is for you to have an accurate understanding of your diagnosis, treatment and support options. An important part of our mission is bringing you the latest information about advances in treatment for non-Hodgkin lymphoma, so you can work with your healthcare team to determine the best options for the best outcomes. Our vision is that one day the great majority of people who have been diagnosed with non-Hodgkin lymphoma will be cured or will be able to manage their disease with a good quality of life. We hope that the information in this publication will help you along your journey. LLS is the world’s largest voluntary health organization dedicated to funding blood cancer research, education and patient services. Since 1954, LLS has been a driving force behind almost every treatment breakthrough for patients with blood cancers, and we have awarded almost $1 billion to fund blood cancer research. Our commitment to pioneering science has contributed to an unprecedented rise in survival rates for people with many different blood cancers. Until there is a cure, LLS will continue to invest in research, patient support programs and services that improve the quality of life for patients and families.
  • Axelrod V. Kite Pharma, Inc. Et

    Axelrod V. Kite Pharma, Inc. Et

    Case 2:17-cv-06684 Document 1 Filed 09/11/17 Page 1 of 26 Page ID #:1 1 Rosemary M. Rivas (State Bar No. 209147) Email: [email protected] 2 LEVI & KORSINSKY, LLP 44 Montgomery Street, Suite 650 3 San Francisco, California 94104 Telephone: (415) 291-2420 4 Facsimile: (415) 484-1294 5 Counsel for Plaintiff Merry Axelrod 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE CENTRAL DISTRICT OF CALIFORNIA 10 MERRY AXELROD, individually and on Case No. 2:17-cv-6684 behalf of all others similarly situated, 11 CLASS ACTION Plaintiff, 12 CLASS ACTION COMPLAINT FOR v. VIOLATION OF SECTIONS 14(d)(4), 13 14(e), AND 20(a) OF THE KITE PHARMA, INC., ARIE SECURITIES EXCHANGE ACT OF 14 BELLDEGRUN, DAVID BONDERMAN, 1934 FARAH CHAMPSI, IAN CLARK, ROY 15 DOUMANI, FRANZ HUMER, JOSHUA JURY TRIAL DEMANDED A. KAZAM, RAN NUSSBAUM, JON 16 PEACOCK, STEVEN B. RUCHEFSKY, OWEN N. WITTE, GILEAD SCIENCES, 17 INC., and DODGE MERGER SUB, INC., 18 Defendants. 19 20 Plaintiff Merry Axelrod (“Plaintiff”), by her attorneys, alleges upon information 21 and belief, except for her own acts, which are alleged on knowledge, as follows: 22 INTRODUCTION 23 1. Plaintiff brings this action on behalf of herself and the public stockholders 24 of Kite Pharma, Inc. (“Kite” or the “Company”) against Kite and members of its Board 25 of Directors (collectively, the “Board” or the “Individual Defendants,” as further defined 26 below, and together with the Company “Defendants”) for violations of Section 14(d)(4), 27 15 U.S.C. § 78n(d)(4), of the Securities and Exchange Act of 1934 (the “Exchange Act”), 28 U.S.
  • Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions

    Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions

    Journal of Clinical Medicine Review Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions David A Bond 1,*, Peter Martin 2 and Kami J Maddocks 1 1 Division of Hematology, The Ohio State University, Columbus, OH 43210, USA; [email protected] 2 Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY 11021, USA; [email protected] * Correspondence: [email protected] Abstract: The increasing number of approved therapies for relapsed mantle cell lymphoma (MCL) provides patients effective treatment options, with increasing complexity in prioritization and se- quencing of these therapies. Chemo-immunotherapy remains widely used as frontline MCL treatment with multiple targeted therapies available for relapsed disease. The Bruton’s tyrosine kinase in- hibitors (BTKi) ibrutinib, acalabrutinib, and zanubrutinib achieve objective responses in the majority of patients as single agent therapy for relapsed MCL, but differ with regard to toxicity profile and dosing schedule. Lenalidomide and bortezomib are likewise approved for relapsed MCL and are active as monotherapy or in combination with other agents. Venetoclax has been used off-label for the treatment of relapsed and refractory MCL, however data are lacking regarding the efficacy of this approach particularly following BTKi treatment. Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies have emerged as highly effective therapy for relapsed MCL, with the CAR-T treatment brexucabtagene autoleucel now approved for relapsed MCL. In this review the authors summarize evidence to date for currently approved MCL treatments for relapsed disease including Citation: Bond, D.A; Martin, P.; sequencing of therapies, and discuss future directions including combination treatment strategies Maddocks, K.J Relapsed Mantle Cell and new therapies under investigation.
  • Mantle Cell Lymphoma

    Mantle Cell Lymphoma

    Leukemia (1998) 12, 1281–1287 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu Mantle cell lymphoma: a retrospective study of 121 cases H Samaha1, C Dumontet1, N Ketterer1, I Moullet1, C Thieblemont1, F Bouafia1, E Callet-Bauchu2, P Felman2, F Berger3, G Salles1 and B Coiffier1 1Service d’He´matologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, and UPRES-JE 1879 ‘He´mopathies Lymphoides malignes’, Universite´ Claude Bernard, Pierre-Be´nite; 2Laboratoire d’He´matologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Be´nite; and 3Laboratoire d’Anatomie Pathologique, Hoˆpital Edouard-Herriot, Hospices Civils de Lyon, France Mantle cell lymphoma (MCL) patients represent a difficult prob- phoma usually begins as a disseminated disease with wide- lem, sometimes to establish the diagnosis but mostly because spread involvement of lymph nodes, spleen, bone marrow of their refractoriness to standard lymphoma treatments. Which treatments to apply and to whom is not yet defined. In this and other extranodal sites, specially the gastrointestinal tract study, we attempted to analyze the clinical features, to identify and Waldeyer ring. However, patients usually present a good the major prognostic factors, and to evaluate the outcome of performance status (PS) at diagnosis although adverse prog- 121 MCL patients treated in our institution between 1979 and nostic factors, such as high serum lactic dehydrogenase (LDH) 1997. Clinical data, treatment modalities, and International and ␤2-microglobulin levels, may be present. Initially, these Prognostic Index (IPI) score were evaluated. Median age was 63 patients usually respond to different types of therapy, but years.
  • Indolent Lymphoma in Dogs

    Indolent Lymphoma in Dogs

    Indolent Lymphoma in Dogs You diagnose indolent lymphoma in a dog. What is indolent lymphoma? What is the prognosis and what are the treatment options? What is indolent lymphoma? Indolent lymphoma (also called small-cell or low-grade lymphoma) is an uncommon form of lymphoma in dogs, representing around 5-29%1 of all canine lymphoma. The subtypes described include follicular lymphoma, marginal zone lymphoma, mantle zone and T-zone lymphoma, which are all derived from B-cells (except for T-zone lymphoma, which is T-cell in origin).2,3 In general, indolent lymphoma is characterised by small lymphocytes, a low mitotic index and slow clinical course of progression. Most dogs with indolent lymphoma present with generalised lymphadenopathy. Some dogs present with solitary lymph node involvement or only splenic involvement. Few dogs present with clinical signs, and if clinical signs are present (including lymphadenopathy), it can wax and wane and is usually mild. T-zone lymphoma (TZL) T-zone lymphoma is the most common subtype in canine indolent lymphoma representing around 60% of dogs with indolent lymphoma.1 TZL is characterised by unique loss of CD45 expression, T-zone distinct histologic pattern and small clear cell cytomorphology.4-6 This subtype is associated with the longest median survival times in dogs with indolent lymphoma.1 Middle-aged to older dogs are primarily affected (median age 8 to 10 years).5 Common breeds affected include Golden retriever (40-50%)6,7 and Shih Tzu.5 There is no apparent gender predilection. Dogs typically present with generalised peripheral lymphadenopathy (that may wax and wane) and/or lymphocytosis with no clinical signs of illness (clinical substage a, 80%).5 If clinical signs are present, it is usually non-specific and mild.